Why it matters: The transaction would rank among the largest pharmaceutical deals ever and create the world\u2019s fourth-largest drugmaker by market value. It would also represent a sharp strategic turn for AstraZeneca, which has spent the past decade building its pipeline through targeted acquisitions and licensing deals rather than another industry-defining merger.<\/p>\n
By the numbers: AstraZeneca was valued at about \u00a3196 billion (\u20ac230 billion) before the report, compared with $133 billion (\u20ac116 billion) for BMS. AstraZeneca shares fell to approximately 7% in early London trading this morning, suggesting investors are unconvinced by the prospect of combining two companies with markedly different growth profiles.<\/p>\n
The strategic logic: BMS would give AstraZeneca even greater scale in the U.S., which already generates nearly half of the UK drugmaker\u2019s revenue. It would also add approved products and clinical programs in oncology, hematology, cardiovascular disease, immunology and neuroscience.<\/p>\n
BMS is not standing still. Its newer medicines generated $7.6 billion (\u20ac6.6 billion) in the second quarter, up 15%, driven by products including Reblozyl, Camzyos, Breyanzi and Opdualag. The company also raised its 2026 revenue forecast<\/a> to between $49 billion and $50 billion (around \u20ac43 billion).<\/p>\n Yes, but: BMS is preparing for major losses of exclusivity. Generic competition has already eroded sales of Revlimid and other older products, while the company estimates that U.S. market exclusivity for both Eliquis and Opdivo could end in 2028, according to its 2025 annual report<\/a>. That creates a difficult proposition for AstraZeneca: BMS offers substantial revenue and a growing portfolio, but also brings a patent cliff that its newer medicines still need to offset.<\/p>\n The antitrust problem: Both companies have extensive cancer portfolios. BMS\u2019 PD-1 inhibitor Opdivo and AstraZeneca\u2019s PD-L1 drug Imfinzi compete in several tumor types, including non-small cell lung cancer. Regulators could therefore demand significant divestments, reducing some of the oncology scale that would ostensibly make the combination attractive.<\/p>\n Between the lines: The talks come shortly after AstraZeneca reaffirmed<\/a> its goal of reaching $80 billion (\u20ac70 billion) in annual revenue by 2030. CEO Pascal Soriot said last week that the company did not \u201cneed M&A to deliver\u201d that target. A deal would also intensify UK concerns about AstraZeneca shifting its center of gravity toward the U.S., where it has expanded its stock market presence and committed to invest $50 billion by 2030.<\/p>\n